Skip to main content

Table 2 Summary of events and characteristics by study

From: Reduced risk of clinically important deteriorations by ICS in COPD is eosinophil dependent: a pooled post-hoc analysis

 

SUN (n = 989)

SHINE (n = 561)

US3 (n = 807)

RISE (n = 1219)

BUD/FORM 160/4.5 μg bid (n = 494)

FORM

4.5 μg bid (n = 495)

BUD/FORM 160/4.5 μg bid (n = 277)

FORM

4.5 μg bid (n = 284)

BUD/FORM 160/4.5 μg bid (n = 404)

FORM

4.5 μg bid (n = 403)

BUD/FORM 160/4.5 μg bid (n = 606)

FORM

4.5 μg bid (n = 613)

Any CID

343 (69.4)

360 (72.7)

173 (62.5)

196 (69.0)

280 (69.3)

305 (75.7)

468 (77.2)

517 (84.3)

Subtypes of first CID

 Exacerbation alone

81 (23.6)

96 (26.7)

47 (27.2)

47 (24.0)

114 (40.7)

126 (41.3)

61 (13.0)

74 (14.3)

 FEV1 event alone

120 (35.0)

112 (31.1)

62 (35.8)

59 (30.1)

90 (32.1)

86 (28.2)

172 (36.8)

174 (33.7)

SGRQ alone

116 (33.8)

112 (31.1)

49 (28.3)

76 (38.8)

61 (21.8)

75 (24.6)

172 (36.8)

171 (33.1)

 Exacerbation + FEV1

3 (0.9)

5 (1.4)

0 (0.0)

2 (1.0)

6 (2.1)

8 (2.6)

5 (1.1)

7 (1.4)

 Exacerbation + SGRQ

3 (0.9)

4 (1.1)

4 (2.3)

2 (1.0)

1 (0.4)

4 (1.3)

6 (1.3)

7 (1.4)

 FEV1 + SGRQ

20 (5.8)

30 (8.3)

10 (5.8)

10 (5.1)

7 (2.5)

5 (1.6)

51 (10.9)

79 (15.3)

 Exacerbation + FEV1 + SGRQ

0 (0)

1 (0.3)

1 (0.6)

0 (0)

1 (0.4)

1 (0.3)

1 (0.2)

5 (1.0)

Individual components

 Exacerbations

152 (30.8)

177 (35.8)

69 (24.9)

78 (27.5)

169 (41.8)

182 (45.2)

151 (24.9)

181 (29.5)

 FEV1 events

196 (39.7)

212 (42.8)

84 (30.3)

100 (35.2)

135 (33.4)

161 (40.0)

289 (47.7)

344 (56.1)

 SGRQ events

188 (38.1)

202 (40.8)

81 (29.2)

116 (40.8)

143 (35.4)

164 (40.7)

312 (51.5)

357 (58.2)

  1. Event rates in percentage of total number of patients; CID sub-events in percentage of total CID events
  2. The rows with individual components (exacerbations, FEV1 events, SGRQ events) describe events as independent variables, whereas the subtypes of first CID events describe the variable/combination occurring first within a patient. Bid, twice daily; BUD Budesonide, CID Clinically Important Deterioration, FEV1 Forced expiratory volume in 1 s, FORM Formoterol, SGRQ St George’s Respiratory Questionnaire